[Hyperparathyroidism--new aspects].
Hyperparathyroidism is generally classified into a primary and secondary form. The primary form is caused by an autonomous adenomatous hypertrophy and/or hyperplasia of parythyroideal glands without known cause in most of the patients. Resulting elevated levels of parathyroid hormone cause elevation of serum calcium, subsequently followed by cerebral symptoms, fatigue and calcinosis of vessels and kidneys. The mainstay of secondary HPT is the initial vitamin D deficiency such as associated with kidney failure. Via an increased PTH secretion, calcium homeostasis will be maintained together with ongoing hyperplasia of the parathyroidea. Therapeutic approaches are related to pathophysiological mechanisms. While surgical removal of adenomatous glands is the mainstay of therapy in primary and late secondary forms, during the still regulated initial period of secondary HPT supplementation of vitamin D and/or sensitation of parathyroideal Calcium-sensing-receptors are therapy of choice.
Kruse
A
A
Klinik und Poliklinik für Nephrologie und Hypertonie, Universitätsspital, Bern.
Beige
J
J
D000236:Adenoma / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D002118:Calcium / Q000097:blood*; D049950:Hyperparathyroidism, Primary / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006962:Hyperparathyroidism, Secondary / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006965:Hyperplasia; D010280:Parathyroid Glands / Q000473:pathology; D010281:Parathyroid Hormone / Q000097:blood*; D010282:Parathyroid Neoplasms / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D016105:Parathyroidectomy; D044169:Receptors, Calcium-Sensing / Q000187:drug effects / Q000502:physiology; D014807:Vitamin D / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*
D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D014807:Vitamin D; D002118:Calcium